FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1436511342> ?p ?o ?g. }

• W1436511342 abstract "Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PAIn non-small cell lung cancer (NSCLC) KRAS-mutant status is a negative prognostic and predictive factor of both classic and target based therapy. In human malignancies bisphosphonate drugs are applied to treat or prevent formation of bone metastases. Nitrogen-containing bisphosphonates inhibit the posttranslational modification of small G-proteins (e.g. Ras, Rac, Rho) and thus may affect proliferation and migration. In our preclinical work, we investigated the effect of an aminobisphosphonate compound (zoledronic acid) on mutant and wild type KRAS-expressing human NSCLC cell lines.In vitro cell viability was measured by MTT assay in H358, LCLC-103H, H1650 and H1975 cells. Apoptotic cell death was quantified by flow cytometric detection of sub-G1-fraction in propidium-iodide stained cultures. Furthermore, we investigated the in vivo effect of zoledronic acid in a SCID mouse subcutaneous xenograft model. The extracted tumors were examined by traditional histological methods and the proportion of proliferating tumor cells was determined by Ki67 labeling.KRAS-mutant H358 human NSCLC cell line showed relative resistance to zoledronic acid on proliferation, while human lung cancer cell lines carried wild type KRAS proved to be sensitive. Zoledronic acid improved the cytostatic effect of traditional anti-cancer agent cisplatin. Zoledronic acid did not induce significant apoptosis in NSCLC cell lines in vitro, rather the blockade of the cell cycle appeared. In in vivo subcutaneous animal model, zoledronic acid significantly reduced the weight of LCLC-103H xenograft tumor harboring wild type KRAS, furthermore, the treatment decreased the number of Ki67-labeled tumor. Zoledronic acid induced the expression of VEGF in LCLC-103H cells and stimulated in vivo angiogenesis.We concluded that in human NSCLC cells the antiproliferative effect of zoledronic acid dependended on KRAS-status (wild-type or mutant). The inhibitory effect of zoledronic manifested through the in vitro and in vivo blockade of cell cycle. The in vivo angiogenic effect of zoledronic acid supported cytostatic effect of cisplatin. Our preclinical investigation suggests that patients with wild type KRAS-expressing NSCLC could potentially benefit from aminobisphosphonate therapy.Citation Format: Istvan Kenessey, Krisztina Koi, Mihaly Cserepes, Judit Dobos, Balazs Hegedűs, Jozsef Tovari, Jozsef Timar. KRAS-mutation dependent effect of zoledronic acid in human NSCLC preclinical models. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 47. doi:10.1158/1538-7445.AM2015-47" @default.
• W1436511342 created "2016-06-24" @default.
• W1436511342 creator A5000161901 @default.
• W1436511342 creator A5007718548 @default.
• W1436511342 creator A5013976072 @default.
• W1436511342 creator A5032882550 @default.
• W1436511342 creator A5067140213 @default.
• W1436511342 creator A5079287831 @default.
• W1436511342 creator A5089545738 @default.
• W1436511342 date "2015-08-01" @default.
• W1436511342 modified "2023-10-18" @default.
• W1436511342 title "Abstract 47: KRAS-mutation dependent effect of zoledronic acid in human NSCLC preclinical models" @default.
• W1436511342 doi "https://doi.org/10.1158/1538-7445.am2015-47" @default.
• W1436511342 hasPublicationYear "2015" @default.
• W1436511342 type Work @default.
• W1436511342 sameAs 1436511342 @default.
• W1436511342 citedByCount "1" @default.
• W1436511342 countsByYear W14365113422016 @default.
• W1436511342 crossrefType "proceedings-article" @default.
• W1436511342 hasAuthorship W1436511342A5000161901 @default.
• W1436511342 hasAuthorship W1436511342A5007718548 @default.
• W1436511342 hasAuthorship W1436511342A5013976072 @default.
• W1436511342 hasAuthorship W1436511342A5032882550 @default.
• W1436511342 hasAuthorship W1436511342A5067140213 @default.
• W1436511342 hasAuthorship W1436511342A5079287831 @default.
• W1436511342 hasAuthorship W1436511342A5089545738 @default.
• W1436511342 hasConcept C121608353 @default.
• W1436511342 hasConcept C126322002 @default.
• W1436511342 hasConcept C143998085 @default.
• W1436511342 hasConcept C150903083 @default.
• W1436511342 hasConcept C185592680 @default.
• W1436511342 hasConcept C190283241 @default.
• W1436511342 hasConcept C207001950 @default.
• W1436511342 hasConcept C2775934118 @default.
• W1436511342 hasConcept C2776326535 @default.
• W1436511342 hasConcept C2776541429 @default.
• W1436511342 hasConcept C2777251235 @default.
• W1436511342 hasConcept C2780783641 @default.
• W1436511342 hasConcept C2781187634 @default.
• W1436511342 hasConcept C31573885 @default.
• W1436511342 hasConcept C502942594 @default.
• W1436511342 hasConcept C526805850 @default.
• W1436511342 hasConcept C55493867 @default.
• W1436511342 hasConcept C62112901 @default.
• W1436511342 hasConcept C71924100 @default.
• W1436511342 hasConcept C86803240 @default.
• W1436511342 hasConceptScore W1436511342C121608353 @default.
• W1436511342 hasConceptScore W1436511342C126322002 @default.
• W1436511342 hasConceptScore W1436511342C143998085 @default.
• W1436511342 hasConceptScore W1436511342C150903083 @default.
• W1436511342 hasConceptScore W1436511342C185592680 @default.
• W1436511342 hasConceptScore W1436511342C190283241 @default.
• W1436511342 hasConceptScore W1436511342C207001950 @default.
• W1436511342 hasConceptScore W1436511342C2775934118 @default.
• W1436511342 hasConceptScore W1436511342C2776326535 @default.
• W1436511342 hasConceptScore W1436511342C2776541429 @default.
• W1436511342 hasConceptScore W1436511342C2777251235 @default.
• W1436511342 hasConceptScore W1436511342C2780783641 @default.
• W1436511342 hasConceptScore W1436511342C2781187634 @default.
• W1436511342 hasConceptScore W1436511342C31573885 @default.
• W1436511342 hasConceptScore W1436511342C502942594 @default.
• W1436511342 hasConceptScore W1436511342C526805850 @default.
• W1436511342 hasConceptScore W1436511342C55493867 @default.
• W1436511342 hasConceptScore W1436511342C62112901 @default.
• W1436511342 hasConceptScore W1436511342C71924100 @default.
• W1436511342 hasConceptScore W1436511342C86803240 @default.
• W1436511342 hasLocation W14365113421 @default.
• W1436511342 hasOpenAccess W1436511342 @default.
• W1436511342 hasPrimaryLocation W14365113421 @default.
• W1436511342 hasRelatedWork W1571150435 @default.
• W1436511342 hasRelatedWork W2054177711 @default.
• W1436511342 hasRelatedWork W2059296838 @default.
• W1436511342 hasRelatedWork W2129391641 @default.
• W1436511342 hasRelatedWork W2149221991 @default.
• W1436511342 hasRelatedWork W2152771219 @default.
• W1436511342 hasRelatedWork W2292303908 @default.
• W1436511342 hasRelatedWork W2330501746 @default.
• W1436511342 hasRelatedWork W2332727808 @default.
• W1436511342 hasRelatedWork W2341580698 @default.
• W1436511342 hasRelatedWork W2539193275 @default.
• W1436511342 hasRelatedWork W2562170609 @default.
• W1436511342 hasRelatedWork W2738587250 @default.
• W1436511342 hasRelatedWork W2761835541 @default.
• W1436511342 hasRelatedWork W2886185950 @default.
• W1436511342 hasRelatedWork W2887201603 @default.
• W1436511342 hasRelatedWork W2954342451 @default.
• W1436511342 hasRelatedWork W2955424014 @default.
• W1436511342 hasRelatedWork W2999667018 @default.
• W1436511342 hasRelatedWork W3026550877 @default.
• W1436511342 isParatext "false" @default.
• W1436511342 isRetracted "false" @default.
• W1436511342 magId "1436511342" @default.
• W1436511342 workType "article" @default.